Work

Supplementary Table S2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors

Year: 2025

Type: supplementary-materials

Abstract: Proteins expression differences between capivasertib-resistant vs. capivasertib-sensitive cells quantified by validated MRM-MS assays as compared to the profile observed in patient samples

DOI: 10.1158/2767-9764.28688265

Authors: Constance A. Sobsey, Bjoern C. Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, Rene P. Zahedi, Elza C. de Bruin, Christoph H. Borchers, Gerald Batist

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4408933675

Cites:

Cited by:

Related to: 10